Nidhi Jyotsana

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Venues

Vanderbilt University

Medizinische Hochschule Hannover (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Vanderbilt University Feb 01 2018

United States

Postdoctoral researcher :: Biomedical Engineering

Education History

Medizinische Hochschule Hannover Aug 01 2010 - Jan 31 2018

Germany

PHD :: Hematology and Oncology

Publications

Hasan Issa, Laura E Swart, Milad Rasouli, Minoo Ashtiani, Sirintra Nakjang, Nidhi Jyotsana, Konstantin Schuschel, Michael Heuser, Helen Blair, Olaf Heidenreich
Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia. Leukemia (2023)
Korie A Grayson, Nidhi Jyotsana, Nerymar Ortiz-Otero, Michael R King
Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes. PloS one 16 (3) (2021)
Sagarajit Mohanty, Nidhi Jyotsana, Amit Sharma, Arnold Kloos, Razif Gabdoulline, Basem Othman, Courteney K Lai, Renate Schottmann, Madhvi Mandhania, Johannes Schmoellerl, Florian Grebien, Euan Ramsay, Anitha Thomas, Hans-Peter Vornlocher, Arnold Ganser, Felicitas Thol, Michael Heuser
Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia. Cancers 12 (10) (2020)
Nidhi Jyotsana, Michael R King
The Impact of COVID-19 on Cancer Risk and Treatment. Cellular and molecular bioengineering (2020)
Arnold Kloos, Konstantinos Mintzas, Lina Winckler, Razif Gabdoulline, Yasmine Alwie, Nidhi Jyotsana, Nadine Kattre, Renate Schottmann, Michaela Scherr, Charu Gupta, Felix Ferdinand Adams, Adrian Schwarzer, Dirk Heckl, Axel Schambach, Suzan Imren, R Keith Humphries, Arnold Ganser, Felicitas Thol, Michael Heuser
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia 34 (11) (2020)
Nidhi Jyotsana, Zhenjiang Zhang, Lauren E Himmel, Fang Yu, Michael R King
Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection. Science advances 5 (7) (2019)

Nidhi Jyotsana.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Nidhi Jyotsana